Sam Brusco, Associate Editor08.01.22
Nevro and Boston Scientific have reached a settlement regarding their ongoing intellectual property lawsuit.
The agreement lets Boston Scientific use the features and capabilities in its current line of products for frequencies below 1,500 Hz, and Nevro has the freedom to operate using features and capabilities in its current product line.
Nevro will give Boston Scientific a global, non-exclusive, non-transferable license to practice paresthesia-free therapy at below 1,500 Hz, and a covenant not to sue for features in any current Boston Scientific products below 1,500 Hz.
Boston Scientific also will grant Nevro a worldwide, non-exclusive, non-transferable license under Boston Scientific's asserted patent families and a covenant not to sue for any features embodied in any current Nevro products.
The settlement concludes all existing litigations between the two companies, and a payment from Boston Scientific to Nevro of $85 million.
The agreement lets Boston Scientific use the features and capabilities in its current line of products for frequencies below 1,500 Hz, and Nevro has the freedom to operate using features and capabilities in its current product line.
Nevro will give Boston Scientific a global, non-exclusive, non-transferable license to practice paresthesia-free therapy at below 1,500 Hz, and a covenant not to sue for features in any current Boston Scientific products below 1,500 Hz.
Boston Scientific also will grant Nevro a worldwide, non-exclusive, non-transferable license under Boston Scientific's asserted patent families and a covenant not to sue for any features embodied in any current Nevro products.
The settlement concludes all existing litigations between the two companies, and a payment from Boston Scientific to Nevro of $85 million.